Cancer treatment and research communications最新文献

{"title":"A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in Taiwan","authors":"Kuo-Ting Lee ,&nbsp;Po-Hsiang Huang ,&nbsp;Chih-Yi Hsu ,&nbsp;Yi-Hsuan Lee ,&nbsp;Hui-Wen Chen ,&nbsp;Yen-Shen Lu ,&nbsp;Jiun-I Lai ,&nbsp;Ta-Chung Chao ,&nbsp;Chun-Yu Liu ,&nbsp;Chi-Cheng Huang ,&nbsp;Yi-Fang Tsai ,&nbsp;Ling-Ming Tseng ,&nbsp;Wei-Chen Yang ,&nbsp;Yu-Ting Huang ,&nbsp;Ching-Ya Huang ,&nbsp;Yu-Ciou Lin","doi":"10.1016/j.ctarc.2025.100893","DOIUrl":"10.1016/j.ctarc.2025.100893","url":null,"abstract":"<div><h3>Background</h3><div>The binary classification of human epidermal growth factor receptor 2 (HER2) as HER2-positive [immunohistochemistry (IHC) 2+/in situ hybridization (ISH)+ or 3+] or HER2-negative (IHC 0, 1+, or 2+/ISH-) has been reassessed due to the efficacy of an anti-HER2 antibody-drug conjugate—Trastuzumab Deruxtecan in HER2-low (IHC 1+ or 2+/ISH-) unresectable/metastatic breast cancer (mBC) patients. However, little is known about the prevalence and outcomes of HER2-low mBC in Taiwan.</div></div><div><h3>Methods</h3><div>This retrospective study rescored archived HER2 IHC slides of HER2-negative unresectable/mBC patients diagnosed from 2017 to 2020. The HER2-low prevalence (among HER2-negative), clinicopathological characteristics, treatments, and outcomes of HER2-low unresectable/mBC patients were investigated.</div></div><div><h3>Results</h3><div>Of the rescored HER2-negative cohort, HER2-low prevalence was 61.2 % (186/304) and slightly higher in slides tested by non-Ventana 4B5 assays (vs. Ventana 4B5) and slides from metastatic sites (vs. primary tumors). The overall percentage agreement between historical and rescored IHC was high (90.1 %). For HR+/HER2-low patients, endocrine therapies were frequently used in the first two lines of treatment, while chemotherapy was more common after the second-line treatment. Chemotherapy was the predominant treatment for HR-/HER2-low patients. Time to next treatment (TTNT) and overall survival (OS) since the first-line systemic therapy were longer in the HR+/HER2-low (N = 138) compared to HR-/HER2-low (N = 48) cohorts (median TTNT: 7.6 vs. 4.8 months; median OS: 37.7 vs. 18.8 months).</div></div><div><h3>Conclusion</h3><div>This study suggested that two-thirds of HER2-negative unresectable/mBC patients in Taiwan were HER2-low. Reassessing the HER2 status of HER2-negative patients could improve treatment strategies with the evolving HER2 classification paradigm.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100893"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience","authors":"Achim Rothe ,&nbsp;Nathalie Bauer ,&nbsp;Lutz Dietze ,&nbsp;Dieter Mainka ,&nbsp;Sonja Lehnert ,&nbsp;Matthias Scheffler","doi":"10.1016/j.ctarc.2025.100891","DOIUrl":"10.1016/j.ctarc.2025.100891","url":null,"abstract":"<div><div>Targeted treatment of non-small cell lung cancer (NSCLC) with driver aberrations has drastically improved the outcome of a subset of patients. However, for successful adaptation in the clinical routine, many stakeholders are involved, like comprehensive cancer centers, molecular pathology, peripheral hospitals, and oncology practices. Here, we present a single center experience in personalized treatment of lung cancer in Germany. Patients with advanced NSCLC and the need for systemic treatment after identification of a targetable driver mutation have been included in this analysis. Detection of the mutations was performed within a diagnostical network. Treatment was chosen depending on the respective driver mutation. We identified 58 patients (26 male, 32 female) with treatment relevant driver mutations: 33 patients (56.9 %) had an <em>EGFR</em> mutation, nine patients (15.5 %) presented with <em>ALK</em> translocation, five patients (8.6 %) were detected to have <em>BRAF</em> mutations, four had <em>ROS1</em> translocations (6.9 %) and 8 patients had <em>MET</em> mutations (13.8 % each). In one patient, concomitant <em>BRAF</em> and <em>MET</em> amplifications were detected. 52 patients received targeted therapy. The median overall survival was 35.5 months (95 % CI, 18.0–52.9 months). 32 patients (64 %) received subsequent treatment after initiation of targeted therapy first-line. Our single-center experience demonstrates that advances in the field of targeted NSCLC therapy are quickly incorporated into clinical routine in Germany. Noteworthy, no new safety information was found.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100891"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data","authors":"Ning Lyu,&nbsp;Zahra Majd,&nbsp;Bilqees Fatima,&nbsp;Zhen Zeng,&nbsp;Hua Chen,&nbsp;Susan Abughosh","doi":"10.1016/j.ctarc.2025.100921","DOIUrl":"10.1016/j.ctarc.2025.100921","url":null,"abstract":"<div><h3>Background</h3><div>Significant advancements have been made in the management of multiple myeloma (MM); however, high relapse rates continue to worsen prognosis and reduce survival for many patients. This study aims to evaluate treatment refractoriness and response rates in individuals with relapsed and/or refractory MM using real-world evidence.</div></div><div><h3>Methodology</h3><div>A retrospective cohort study utilizing commercial registry data for 2022, included individuals with relapsed and/or refractory MM who are 18–79 years old and obtain minimum of 5 lines of therapy. Patients at least have one proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-targeting monoclonal antibody (CD38 MoAB), with their last MM-related visit before October 2022. Patients were excluded if they had concurrent primary malignancies or documented death within 28 days of last line of treatment initiation. Descriptive data, including patient demographic and clinical characteristics, were summarized using continuous and categorical variables.</div></div><div><h3>Results</h3><div>We identified 283 patients after applying inclusion and exclusion criteria. 35.7 % of patients have an overall response rate with median response duration of 6.3 months. Most of patients were found to be categorized in penta-refractory class (33.6 %), followed by triple-refractory (25.4 %), dual-refractory (19.4 %), and not triple-refractory classes (13.4 %). The response rate was 49.1% in dual-class refractory, 22.2 % in triple-class refractory, 44.7 % in not triple-class refractory, and 33.7 % in penta-class refractory patients.</div></div><div><h3>Conclusion</h3><div>Findings imply that substantial proportion of patients continue to show limited treatment response and treatment refractoriness even after multiple lines of therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100921"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada","authors":"William J Phillips ,&nbsp;Horia Marginean ,&nbsp;Mohammad Alrehaili ,&nbsp;Arwa Ahmed Abdelrahim ,&nbsp;Tim Asmis ,&nbsp;Mike Vickers ,&nbsp;Benjamin Yeung ,&nbsp;Bryan Lo ,&nbsp;Rachel Goodwin","doi":"10.1016/j.ctarc.2025.100896","DOIUrl":"10.1016/j.ctarc.2025.100896","url":null,"abstract":"<div><h3>Background</h3><div>BRAF V600E mutations are identified in 10 % of metastatic colorectal cancer (mCRC) cases. In this project, we evaluated the clinicopathologic features and natural history of patients with BRAF mutant (BRAF-mt) mCRC prior to era of BRAF targeted therapy.</div></div><div><h3>Methods</h3><div>This is a retrospective project evaluating patients with diagnosed with mCRC with an identified BRAF V600E mutation between January 1, 2015 and December 31, 2021 seen at the Ottawa Hospital Cancer Centre prior to the approval of cetuximab and encorafenib in Canada. Demographic, clinical, and cancer characteristics were collected from the medical records. Outcomes of interest included overall survival (OS) and time to next therapy (TNT).</div></div><div><h3>Results</h3><div>71 patients were included. The median age was 69 years, 37 (52 %) patients were females, and 19 (27 %) were mismatch repair deficient (dMMR). Median OS was 12.9 months with 21 (30 %) patients living greater than 2-years. Signet ring histology (HR=7.27, <em>p</em> &lt; 0.001), peritoneal metastasis (HR=2.29, 0.003), distant lymphatic metastasis (HR=2.70, <em>p</em> &lt; 0.001), brain metastasis (HR=2.86, <em>p</em> &lt; 0.048) and metastatectomy (HR=0.17, <em>p</em> &lt; 0.001) were associated with OS. Forty-six (65 %) patients received first-line systemic therapy, 14 (20 %) second-line and 2 (3 %) third-line. Median duration of therapy was 8.5 months for first-line, 5.5 months for second-line and 1.5 months for third-line.</div></div><div><h3>Conclusion</h3><div>Real world data demonstrates that patients with BRAF-V600E mCRC have poor clinical outcomes with traditional systemic therapies. Only a minority of patients received second- or third-line systemic treatments, highlighting the importance of ongoing research evaluating incorporation of targeted therapy in first-line treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100896"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of pancreatic elastase-1 measurement during health checkups for detection of pancreatic cancer in asymptomatic individuals","authors":"Haruka Itoh ,&nbsp;Satomi Asai ,&nbsp;Shinji Takashimizu ,&nbsp;Toshio Nakagohri ,&nbsp;Yasuhiro Nishizaki ,&nbsp;Hayato Miyachi","doi":"10.1016/j.ctarc.2025.100951","DOIUrl":"10.1016/j.ctarc.2025.100951","url":null,"abstract":"<div><h3>Objectives</h3><div>Early detection of pancreatic cancer before symptom onset improves curability. This study evaluated the utility of blood elastase-1 as a screening tool for pancreatic cancer in asymptomatic individuals.</div></div><div><h3>Methods</h3><div>A total of 200,583 individuals underwent health checkups at the Tokai University Hospital Health Screening Center between July 2005 and December 2018. The incidence of pancreatic cancer was compared among individuals with blood elastase-1 levels ≥401 ng/dL or &lt;401 ng/dL at health checkups.</div></div><div><h3>Results</h3><div>Among 376 individuals with elastase-1 levels ≥401 ng/dL (high group), 12 were diagnosed with pancreatic cancer at our hospital. Among 200,207 records with elastase-1 levels &lt;401 ng/dL (low group), an estimated 41 individuals developed pancreatic cancer. The sensitivity and specificity of elastase-1 testing for pancreatic cancer detection was 22.6 % and 99 %, respectively. The sensitivity of abdominal ultrasonography was 50 % and increased to 68.8 % when combined with elastase-1 testing. In patients diagnosed with pancreatic cancer, the elastase-1-high group was more likely to undergo surgery, as compared with the elastase-1-low group (75 % [9/12] vs. 50 % [10/20], statistically not signifcant, p= 0.267), and had significantly longer overall survival (median: 1113 days and 641 days).</div></div><div><h3>Conclusions</h3><div>Incorporating elastase-1 testing alongside abdominal ultrasonography in routine health checkups may improve the detection of pancreatic cancer in asymptomatic individuals. Patients whose pancreatic cancer was identified due to elevated elastase-1 levels had a better prognosis compared to those diagnosed through other methods.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100951"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing of low risk endometrial cancer patients with isolated local recurrences","authors":"Shuhua Zheng,&nbsp;Yirong Liu,&nbsp;Paul D. Kinkopf,&nbsp;Amulya Yalamanchili,&nbsp;Jonathan B. Strauss,&nbsp;Eric D. Donnelly","doi":"10.1016/j.ctarc.2025.100890","DOIUrl":"10.1016/j.ctarc.2025.100890","url":null,"abstract":"<div><h3>Introduction</h3><div>A small proportion of clinicopathologically low-risk endometrial cancer (EC) patients who omitted adjuvant radiotherapy (RT) may subsequently develop a local recurrence. Molecular profile for those clinically low-risk yet recurred EC patients is unavailable.</div></div><div><h3>Methods</h3><div>A total of 442 EC patients treated from 2014 to 2020 at Northwestern Memorial Hospital were studied. Among them, 28 patients clinically low risk or low-intermediate risk per GOG-99 criteria developed an isolated local recurrence after hysterectomy, bilateral salpingo-oophorectomy, and omitted RT. Whole exome sequencing (WES) was performed on 22 patients whose pathologic specimen were retrievable.</div></div><div><h3>Results</h3><div>The majority of the cases studied were molecularly No Specific Molecular Profile (NSMP) cohort (91%). We identified <em>CTNNB1, FGFR2, PTEN</em>, and <em>KRAS</em> as the most frequently altered pathogenic or likely pathogenic genes with 5 (22.7%), 5 (22.7%), 4 (18.2%), and 3 (13.6%) out of 22 patients carrying these alterations, respectively. <em>TP53</em> somatic alterations were identified in 2 (9.1%) out of 22 cases. Analysis of The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA-UCEC) dataset identified 53 EC patients with pathologically Grade 1 molecularly NSMP cohort. Within this cohort, <em>CTNNB</em>1 alterations were identified in 31 patients (58%) and prognosticated worse progression free survival (<em>p</em>&lt;0.05).</div></div><div><h3>Conclusion</h3><div>NSMP molecular group constitutes the majority of clinically low-risk EC patients with isolated local recurrences. The <em>CTNNB1</em> alteration was validated as a biomarker in prognostication in this independent cohort and may help guide adjuvant treatment decisions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100890"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis as the new approach to cancer therapy","authors":"Oluwafemi Adeleke Ojo ,&nbsp;Susan Grant ,&nbsp;Pearl Ifunanya Nwafor-Ezeh ,&nbsp;Tobiloba Christiana Maduakolam-Aniobi ,&nbsp;Tolulope Isaiah Akinborode ,&nbsp;Emmanuel Henry Ezenabor ,&nbsp;Adebola Busola Ojo","doi":"10.1016/j.ctarc.2025.100913","DOIUrl":"10.1016/j.ctarc.2025.100913","url":null,"abstract":"<div><div>Cancer is characterized by unregulated cell proliferation, evasion of apoptosis, and a propensity for metastasis, making it a leading cause of morbidity and mortality globally. Major challenges in cancer treatment include drug resistance and tumor heterogeneity, which hinder the clinical efficacy of existing therapies. To enhance treatment outcomes, it is essential to integrate emerging biological insights and technological advancements with conventional therapeutic strategies. Recent research has identified various forms of cell death, which can be classified as either regulated or unregulated. Regulated cell death involves specific biochemical and signaling pathways, while unregulated cell death occurs passively and uncontrollably. Apoptosis, the most extensively studied form of regulated cell death, is primarily mediated by the activation of caspase proteases. Nevertheless, the resistance of many tumors to apoptotic pathways has shifted focus towards non-apoptotic forms of cell death, such as ferroptosis. Ferroptosis is an iron-dependent form of regulated necrosis characterized by extensive membrane damage resulting from lipid peroxidation. Numerous preclinical studies have demonstrated that inducing ferroptosis can significantly reduce tumor growth across a variety of cancer types. For instance, in a study involving breast cancer models, the use of ferroptosis inducers such as erastin and RSL3 led to a marked decrease in tumor volume and weight.</div><div>This review aims to explore the potential of ferroptosis as a novel therapeutic strategy in cancer treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100913"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer","authors":"Aoife Carr ,&nbsp;Jonathan A. Coulter ,&nbsp;Julie Workman ,&nbsp;Joanna Fay ,&nbsp;Angela Farrelly ,&nbsp;Alex J. Eustace ,&nbsp;Lindsey Bennie ,&nbsp;Liam Grogan ,&nbsp;Oscar Breathnach ,&nbsp;Patrick G. Morris ,&nbsp;Deborah A. McNamara ,&nbsp;Mattia Cremona ,&nbsp;Brian D.P. O'Neill ,&nbsp;Bryan T. Hennessy ,&nbsp;Sinead Toomey","doi":"10.1016/j.ctarc.2025.100926","DOIUrl":"10.1016/j.ctarc.2025.100926","url":null,"abstract":"<div><div>Responses to neoadjuvant chemoradiotherapy for locally advanced rectal cancer are not uniform. The phosphatidylinositol-3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways are involved in tumorigenesis and treatment resistance in many cancers; therefore, targeting these pathways could enhance response to chemoradiotherapy.</div><div>A panel of colorectal cancer (CRC) cell lines (<em>n</em> = 10) with varying PI3K and MAPK mutational backgrounds were treated with combinations of 5-Flourouracil (5-FU), radiation, the PI3K inhibitor copanlisib, and/or the MEK inhibitor refametinib, and their effects on proliferation <em>in vitro</em> were measured. BALB/c SCID mice were implanted with CRC cell lines representative of each mutational background, treated with copanlisib and/or chemoradiotherapy, and monitored for tumor growth.</div><div><em>In vitro, PIK3CA</em> mutated cell lines were most sensitive to copanlisib (IC50=28 nM) and <em>KRAS</em> mutated cell lines were most sensitive to refametinib (IC50 = 36 nM), while the combination of copanlisib and refametinib was synergistic in 9/10 cell lines tested. The addition of copanlisib to 5-FU chemoradiotherapy inhibited cell growth compared to 5-FU chemoradiotherapy alone, an effect that was most notable in LS-1034 (<em>KRAS</em> mutated) and Caco-2 (<em>PIK3CA/KRAS</em> wild-type) cell lines. <em>In vivo</em> copanlisib and 5-FU chemoradiotherapy reduced tumor growth in all xenograft models and increased overall survival in LS-1034 and Caco-2 xenografts.</div><div>Our results suggest that activation of the kinase signalling pathway may modulate PI3K/MEK inhibitor responsiveness in colorectal cancer. Furthermore, the addition of copanlisib to 5-FU chemoradiotherapy resulted in an enhanced anti-proliferative cytotoxic effect compared to 5-FU chemoradiotherapy alone, regardless of the background mutational status, and supports further clinical development of this regimen.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100926"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of long non-coding RNAs in developing paclitaxel-resistant triple negative breast cancer: a systematic review","authors":"Davood Dalil ,&nbsp;Saeid Iranzadeh ,&nbsp;Alireza Barouh ,&nbsp;Zahra Ghorbanniadelavar ,&nbsp;Mohammad Mahdi Mehrabi","doi":"10.1016/j.ctarc.2025.100936","DOIUrl":"10.1016/j.ctarc.2025.100936","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent evidence supports the idea that long non-coding RNAs (lncRNAs) are significantly involved in chemoresistance of breast cancer. This study aimed to systematically review the emerging role of lncRNAs in paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC). Furthermore, the review summarized potential targets and the underlying mechanisms of lncRNAs to induce or reverse the resistance of TNBC cells to PTX.</div></div><div><h3>Methods</h3><div>The PubMed, Scopus, and Web of Science databases were searched for studies on lncRNAs involved in the resistance of TNBC cells to PTX using specific terms related to TNBC, lncRNAs, resistance, and paclitaxel. Relevant English articles published until November 2023, were systematically reviewed based on inclusion and exclusion criteria. Quality of the included studies was assessed using the Würzburg Methodological Quality Score (W-MeQS) by two independent authors.</div></div><div><h3>Results</h3><div>A total of 95 publications were initially identified, and after applying the inclusion and exclusion criteria, 19 articles were included in this systematic review. These studies investigated the role of critical lncRNAs in PTX-resistant TNBC. Regulating the cell cycle and apoptosis, epithelial-to-mesenchymal transition, autophagy, and angiogenesis are the main mechanisms through which lncRNAs affect the resistance to PTX in TNBC.</div></div><div><h3>Conclusion</h3><div>This systematic review highlights the significant role of lncRNAs in promoting or inhibiting the resistance of TNBC cells to PTX. The lncRNAs with upregulated or downregulated expression in PTX-resistant TNBC may provide promising therapeutic targets to enhance the efficacy of chemotherapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100936"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human malignant ovarian germ cell tumor cell lines derived from peritoneal cytology retrieving from circulating tumor cell system","authors":"Jie Yang ,&nbsp;Xinyue Zhang ,&nbsp;Jie Tang ,&nbsp;Xiaolei Fu ,&nbsp;Qiong Wu ,&nbsp;Hong Li ,&nbsp;Rui Chen ,&nbsp;Jiaxin Yang","doi":"10.1016/j.ctarc.2025.100934","DOIUrl":"10.1016/j.ctarc.2025.100934","url":null,"abstract":"<div><h3>Background</h3><div>Malignant ovarian germ cell tumor (MOGCT) is a rare neoplasm predominantly affecting adolescent and young adult females. Establishing personalized permanent tumor cell lines is crucial for understanding tumor behavior and optimizing precision treatment for these patients.</div></div><div><h3>Methods</h3><div>We developed a novel procedure for isolating and culturing human MOGCT cells from peritoneal wash cytology using the circulating cell extraction technique (Labyrinthbiotech Co. LLC, LABYRINTH<img>CE01, China).</div></div><div><h3>Result</h3><div>Peripheral blood and peritoneal washings were collected from 15 patients, including those with yolk sac tumor (n = 6), dysgerminoma (n = 2), immature teratoma (n = 5), and mixed germ cell tumor (n = 2). After washing and centrifugation, samples were processed using the labyrinth technique to achieve high-purity cell cultures. The isolated tumor cells were characterized by immunofluorescence microscopy and flow cytometry. Immunohistochemical analysis enabled specific discrimination from primary peritoneal human fibroblasts. Cultures were established from peritoneal cytology with cell densities ranging from 10² to 10⁵ cells per well, with 5 samples showing over 10⁵ cell growth, 3 samples over 10⁴ cell growth, and others at 10³ cell growth. The longest cell culture has been maintained for 18 generations. Short tandem repeat (STR) analysis of cultured cells confirmed their germ cell tumor origin. Preliminary assessments of chemosensitivity in cultured cells have been found to reflect similar clinical responses in the corresponding patients.</div></div><div><h3>Conclusion</h3><div>The MOGCT cell lines derived from peritoneal washings using the circulating tumor cell chip represent the tumor characteristics. This method holds promise for functional studies on rare ovarian tumors and for evaluating chemo-sensitivity for potential therapeutic applications.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100934"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}